CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017
administered orally twice a day in combination with erlotinib, and to assess the
pharmacokinetics of CS-7017 in combination with erlotinib.